Form 4: Singular Genomics Systems COO Settles Restricted Stock Units

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, settled vested Restricted Stock Units (RSUs) on August 9, 2024, receiving 250 shares of common stock.

Summary

• On August 9, 2024, Jyotsna Ghai, the Chief Operating Officer of Singular Genomics Systems, settled vested Restricted Stock Units (RSUs).
• This transaction resulted in the acquisition of 250 shares of Common Stock.
• The shares were issued pursuant to the settlement of vested RSUs, where each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• Following the transaction, Ms. Ghai beneficially owns 600 shares of Common Stock.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on June 26, 2024.
• The RSUs vest in 16 equal quarterly installments over four years, starting from February 9, 2024.
• Ms. Ghai directly owns 3,500 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive compensation and stock ownership.

Key Dates